Multiple myeloma trials in Australia

In Australia 51 Also abroad 703

51 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Brisbane, Camperdown, Melbourne
Age
18 years and over
People
230 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06297226
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Camperdown, Darlinghurst, Fitzroy, Liverpool, Melbourne, Murdoch
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 1Taking people
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Where
Clayton, Fitzroy, Melbourne, Waratah, Wollongong
Age
18 years and over
People
276 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06768489 · EU 2024-515316-44-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Darlinghurst, Garran, Heidelberg, Macquarie University, Melbourne, Perth, Port Macquarie
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 1Taking people
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Where
Perth
Age
18 years and over
People
258 worldwide
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07477587
Phase 1Taking people
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Where
Camperdown, Melbourne
Age
18 years and over
People
70 worldwide
Run by
Kelonia Therapeutics, Inc.
See details and how to joinNCT07075185
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Benowa, Clayfield, East Melbourne, Fitzroy, Geelong, Greenslopes, Melbourne, Perth, Richmond, Woolloongabba
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Birtinya, Blacktown, Brisbane, Concord, Fitzroy, Geelong, Nedlands
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Fitzroy, Nedlands
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Concord, Darlinghurst, East Melbourne, Fitzroy, Liverpool, Melbourne, Murdoch, Waratah
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 1/2Taking people
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Adelaide, Benowa, Melbourne, Sydney, Wollongong
Age
18 years and over
People
186 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06669247 · EU 2024-513126-39-00
Phase 3Not yet taking people in Australia
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Benowa, Melbourne, Murdoch, Nedlands, Richmond, South Brisbane, Wollongong
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
Phase 4Taking people
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
Where
Melbourne, Richmond
Age
18 years and over
People
80 worldwide
Run by
Pfizer
See details and how to joinNCT06057402 · EU 2023-505200-33-00
Phase 1Taking people
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
Where
Melbourne
Age
18 years and over
People
12
Run by
Peter MacCallum Cancer Centre, Australia
See details and how to joinNCT07541391
Phase 1Taking people
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Where
Blacktown, Melbourne, Nedlands, Wollongong
Age
18 years and over
People
135 worldwide
Run by
AbbVie
See details and how to joinNCT06896916 · EU 2024-512146-41-00
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Box Hill, Fitzroy, Gosford NSW, Herston, Melbourne, St Leonards
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Phase 1Taking people
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Where
Benowa, Concord, Fitzroy, Melbourne, Nedlands
Age
18 years and over
People
200 worldwide
Run by
Ichnos Sciences SA
See details and how to joinNCT05862012 · EU 2023-507071-21-01
Phase 1Taking people
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Where
Melbourne, Wollongong
Age
18 years and over
People
87 worldwide
Run by
Sanofi
See details and how to joinNCT06630806
Phase 3Taking people
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Where
Adelaide, Box Hill, Canberra, Geelong, Heidelberg, Kingswood, Melbourne, Sunshine Coast
Age
18 years and over
People
1,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00
No phaseTaking people
European Myeloma Network (EMN) Sample Project
Where
Melbourne
Age
18 years and over
People
6,000 worldwide
Run by
European Myeloma Network B.V.
See details and how to joinNCT06237803
Phase 2/3Taking people
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Where
Adelaide, Melbourne
Age
18 years and over
People
900
Run by
Monash University
See details and how to joinNCT07202052
Phase 2/3Taking people
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Where
Adelaide, Melbourne
Age
18 years and over
People
900
Run by
Monash University
See details and how to joinNCT07202065
Phase 2/3Taking people
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Where
Adelaide, Melbourne
Age
18 years and over
People
900
Run by
Monash University
See details and how to joinNCT07202078
Phase 2/3Taking people
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
Where
Adelaide, Melbourne
Age
18 years and over
People
900
Run by
Monash University
See details and how to joinNCT07202091
Phase 1/2Taking people
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Where
Heidelberg, Melbourne, Wollongong
Age
18 years and over
People
116 worldwide
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT06083207